Bouyahya A, Mechchate H, Oumeslakht L, Zeouk I, Aboulaghras S, Balahbib A, Zengin G, Kamal MA, Gallo M, Montesano D, Omari NE. The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions. Biomolecules. 2022;12(3):367–367. https://doi.org/10.3390/biom12030367.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Adhikari S, Bhattacharya A, Adhikary S, Singh V, Gadad SS, Roy S, Das C. The paradigm of drug resistance in cancer: an epigenetic perspective. Biosci Rep. 2022. https://doi.org/10.1042/bsr20211812.

Article  PubMed  PubMed Central  Google Scholar 

Akhoundova D, Rubin MA. Clinical application of advanced multi-omics tumor profiling: shaping precision oncology of the future. Cancer Cell. 2022;40(9):920–38. https://doi.org/10.1016/j.ccell.2022.08.011.

Article  PubMed  CAS  Google Scholar 

Majchrzak-Celińska A, Warych A, Szoszkiewicz M. Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing. Genes. 2021;12(2):208–208. https://doi.org/10.3390/genes12020208.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Babar Q, Saeed A, Tabish TA, Pricl S, Townley H, Thorat N. Novel epigenetic therapeutic strategies and targets in cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2022;1868(12):166552–166552. https://doi.org/10.1016/j.bbadis.2022.166552.

Article  PubMed  CAS  Google Scholar 

Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303–22. https://doi.org/10.1038/s41568-020-0253-2.

Article  PubMed  CAS  Google Scholar 

Borcoman E, Kamal M, Marret G, Dupain C, Castel-Ajgal Z, Le Tourneau C. HDAC inhibition to prime immune checkpoint inhibitors. Cancers. 2021;14(1): 66. https://doi.org/10.3390/cancers14010066.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Brown LJ, Achinger-Kawecka J, Portman N, Clark S, Stirzaker C, Lim E. Epigenetic therapies and biomarkers in breast cancer. Cancers (Basel). 2022;14(3):474–474. https://doi.org/10.3390/cancers14030474.

Article  PubMed  CAS  Google Scholar 

Cervena K, Siskova A, Buchler T, Vodicka P, Vymetalkova V. Methylation-based therapies for colorectal cancer. Cells. 2020;9(6):1540–1540. https://doi.org/10.3390/cells9061540.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen H, Gao S, Liu W, Wong C-C, Wu J, Wu J, Liu D, Gou H, Kang W, Zhai J, Li C, Su H, Wang S, Soares F, Han J, He HH, Yu J. RNA N6-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the m6A-GLUT1-mTORC1 axis and is a therapeutic target. Gastroenterology. 2020;160(4):1284-1300.e16. https://doi.org/10.1053/j.gastro.2020.11.013.

Article  PubMed  CAS  Google Scholar 

Chen L, Shan G. Circrna in cancer: fundamental mechanism and clinical potential. Cancer Lett. 2021;505:49–57. https://doi.org/10.1016/j.canlet.2021.02.004.

Article  PubMed  CAS  Google Scholar 

Chen L, He M, Zhang M, Sun Q, Zeng S, Zhao H, Yang H, Liu M, Ren S, Meng X, Xu H. The role of non-coding RNAs in colorectal cancer, with a focus on its autophagy. Pharmacol Ther. 2021;226:107868–107868. https://doi.org/10.1016/j.pharmthera.2021.107868.

Article  PubMed  CAS  Google Scholar 

Chen Y, Pan C, Wang X, Xu D, Ma Y, Hu J, Chen P, Xiang Z, Rao Q, Han X. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells. Theranostics. 2021;11(16):7640–57. https://doi.org/10.7150/thno.61178.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cheng K, Cai N, Zhu J, Yang X, Liang H, Zhang W. Tumor-associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun. 2022;42(11):1112–40. https://doi.org/10.1002/cac2.12345.

Article  Google Scholar 

Conteduca V, Hess J, Yamada Y, Ku S-Y, Beltran H. Epigenetics in prostate cancer: clinical implications. Transl Androl Urol. 2021;10(7):3104–16. https://doi.org/10.21037/tau-20-1339.

Article  PubMed  PubMed Central  Google Scholar 

Cui J, Li G, Yin J, Li L, Tan Y, Wei H, Liu B, Deng L, Tang J, Chen Y, Yi L. GSTP1 and cancer: expression, methylation, polymorphisms and signaling (Review). Int J Oncol. 2020. https://doi.org/10.3892/ijo.2020.4979.

Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021;20(1): 171. https://doi.org/10.1186/s12943-021-01464-x.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Das D, Karthik N, Taneja R. Crosstalk between inflammatory signaling and methylation in cancer. Front Cell Dev Biol. 2021. https://doi.org/10.3389/fcell.2021.756458.

Article  PubMed  PubMed Central  Google Scholar 

Das K, Mohan V. The role of microRNAs in inflammation. Int J Mol Sci. 2022;23(24):15479–15479. https://doi.org/10.3390/ijms232415479.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Di Agostino S, Vahabi M, Turco C, Fontemaggi G. Secreted non-coding RNAs: functional impact on the tumor microenvironment and clinical relevance in triple-negative breast cancer. Non-coding RNA. 2022;8(1): 5. https://doi.org/10.3390/ncrna8010005.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Karati D, Mukherjee S, Roy S. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator. Med Oncol. 2024. https://doi.org/10.1007/s12032-024-02303-x.

Article  PubMed  Google Scholar 

Bhagirath D, Liston M, Akoto T, Lui B, Bensing BA, Sharma A, Saini S. Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients. Sci Rep. 2021. https://doi.org/10.1038/s41598-021-87441-2.

Article  PubMed  PubMed Central  Google Scholar 

Du Y, Yuan Y, Xu L, Zhao F, Wang W, Xu Y, Tian X. Discovery of METTL3 small molecule inhibitors by virtual screening of natural products. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.878135.

Article  PubMed  PubMed Central  Google Scholar 

Fath MK, Azargoonjahromi A, Kiani A, Jalalifar F, Osati P, Oryani MA, Shakeri F, Nasirzadeh F, Khalesi B, Nabi-Afjadi M, Zalpoor H, Mard-Soltani M, Payandeh Z. The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cell Mol Biol Lett. 2022. https://doi.org/10.1186/s11658-022-00344-6.

Article  Google Scholar 

Feng S, De DD. Clinical advances in targeting epigenetics for cancer therapy. FEBS J. 2021;289(5):1214–39. https://doi.org/10.1111/febs.15750.

Article  PubMed  CAS  Google Scholar 

French R, Pauklin S. Epigenetic regulation of cancer stem cell formation and maintenance. Int J Cancer. 2020;148(12):2884–97. https://doi.org/10.1002/ijc.33398.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gao Y, You M, Fu J, Tian M, Zhong X, Du C, Hong Z, Zhu Z, Liu J, Markowitz GJ, Wang F-S, Yang P. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. J Hepatol. 2021;76(1):148–59. https://doi.org/10.1016/j.jhep.2021.08.029.

Article  PubMed  CAS  Google Scholar 

Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL, Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021. https://doi.org/10.1038/s41467-021-22024-3.

Article  PubMed